Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Non-Current Assets (2016 - 2026)

Ironwood Pharmaceuticals' Other Non-Current Assets history spans 17 years, with the latest figure at $4.5 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets fell 23.99% to $4.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.5 million, a 23.99% decrease, with the full-year FY2025 number at $4.5 million, down 23.99% from a year prior.
  • Other Non-Current Assets hit $4.5 million in Q4 2025 for Ironwood Pharmaceuticals, down from $4.8 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for IRWD hit a ceiling of $6.3 million in Q3 2024 and a floor of $485000.0 in Q1 2021.
  • Historically, Other Non-Current Assets has averaged $2.6 million across 5 years, with a median of $2.1 million in 2021.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 48.57% in 2021 and later soared 734.71% in 2024.
  • Tracing IRWD's Other Non-Current Assets over 5 years: stood at $485000.0 in 2021, then rose by 3.09% to $500000.0 in 2022, then surged by 621.6% to $3.6 million in 2023, then soared by 64.16% to $5.9 million in 2024, then decreased by 23.99% to $4.5 million in 2025.
  • Business Quant data shows Other Non-Current Assets for IRWD at $4.5 million in Q4 2025, $4.8 million in Q3 2025, and $5.2 million in Q2 2025.